Table 7 Liquid biopsy in respiratory system cancers
From: Liquid biopsy in cancer: current status, challenges and future prospects
Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
LC | cfDNA methylation | Plasma | up | Â | Early diagnostic biomarker | |
CDO1, HOXA9, AJAP1, PTGDR, UNCX, MARCH11 methylation | Serum, Pleural effusion, Ascites | up | Â | Early diagnostic biomarker, Prognostic biomarker | ||
RASSF1A, CDKN2A, DLEC1 methylation | Plasma | up | Â | Early diagnostic biomarker | ||
ctDNA | Plasma | up | Â | Efficacy monitoring biomarker | ||
CTCs | Peripheral blood | up | Â | Early diagnostic biomarker | ||
let-7i-3p, miR-154-5p | Serum | down | Â | Early diagnostic biomarker | ||
miRNA | Plasma exosome | up | Â | Early diagnostic biomarker | ||
SSA1,SSA2 | Serum, Plasma | up | MMP-9 | Early diagnostic biomarker, Tumor aggressiveness biomarker | ||
LSCC | ctDNA | Plasma, Saliva | up | Â | Early diagnostic biomarker | |
ctDNA methylation | Plasma | up | Â | Early diagnostic biomarker, Disease progression biomarker, Prognostic biomarker, Disease progression biomarker | ||
CTCs | Peripheral blood | up | Â | Early diagnostic biomarker | ||
CTCs | Peripheral blood | up | Â | Prognostic biomarker, Efficacy monitoring biomarker | ||
CTCs | Peripheral blood | up | Â | Prognostic biomarker | ||
miR-21 | Serum exosome | up | Â | Early diagnostic biomarker | ||
miR-155 | Plasma | up | Â | Early diagnostic biomarker | ||
miRNA-130a | Plasma | down | Â | Disease progression biomarker | ||
miR-632 | Serum | up | Â | Early diagnostic biomarker, Prognostic biomarker | ||
Microbiota | Mouthwash | Â | Â | Early diagnostic biomarker | ||
NPC | EBV DNA | Plasma | up | Â | Early diagnostic biomarker, Tumor recurrence biomarker | |
EBV DNA | Plasma | up | Â | Efficacy monitoring biomarker | ||
EBV DNA methylation | Saliva | up | Â | Early diagnostic biomarker | ||
EBV microRNA | Serum | up | Â | Early diagnostic biomarker |
